Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
Not a traditional drug phase: Intravenous injection of 68Ga-YQ-CC05 for PET-CT examination for Medullary Thyroid Carcinoma
Measure the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.
Tumor patients who can obtain the final pathological results
Kidney: GFR \> 50 ml/min, ERPF \> 280 ml/min, platelet count (PLT) \> 75,000/μL, white blood cell (WBC) \> 3,000/μL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 times the normal value
Who the registry excludes
Individuals with a history of allergy to similar drugs (drugs with similar chemical or biological components to CCK2R), allergic constitution, or current allergic diseases;
Those who are currently participating in other clinical drug studies, or have previously participated in any clinical drug studies (excluding vitamins and minerals);
Other uncontrollable clinical issues (such as HIV, hepatitis C virus infection, active hepatitis B, or other severe chronic infections, as well as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases);
Red blood cells (RBC) count less than 4×10\^12, white blood cells (WBC) count less than 3×10\^9, hemoglobin level less than 110g/L, and platelet count (PLT) less than 75,000×10\^9;
Obvious abnormalities in liver and kidney function, with GFR less than 50 ml/min;
Tumor burden greater than 50%, or significant spinal cord compression;
Expected survival duration less than half a year; chemotherapy within 6 months;
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate.
The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07914764?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07914764?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.